The incidence of prostate cancer is the first male tumor in the United States, and the mortality rate is the second highest. In recent years, with changes in the environment and diet, the incidence of prostate cancer in Chinese people has jumped to the first place of urological tumors, and is climbing at a rate of 10% per year. The prostate gland is located in the pelvis of the human body, around the beginning of the urethra, and is the male reproductive organ. The normal development of the prostate gland and the occurrence and progression of prostate cancer depend on human androgens, which can be compared to the “food” of cancer cells, so removing most of the androgens through surgical debridement or drug debridement makes the prostate cancer tissue shrink and the cancer cells undergo apoptosis, which is commonly known as “starving” the cancer cells. “Starving” is the main method of treating advanced prostate cancer. This androgen stripping treatment initially has good efficacy, the prostate-specific antigen, or PSA, which marks the progression of the disease, drops dramatically and the disease is in a very stable state. However, after 18 to 24 months, the prostate cancer progresses to Castration Resistant Prostate Cancer (CRPC), which means that the androgen blockade therapy that was working so well is no longer effective, the tumor starts to progress again, PSA rises, bone metastases or metastases from other sites worsen, and the patient becomes very frightened. The patient is very frightened. Why does this change in resistance occur? Scientific studies have shown that the transformation of destructive resistance and distant metastasis of prostate cancer is a very complex process, with multiple theories competing and multiple mechanisms participating and interacting with each other, such as: mutations in androgen receptor genes; upregulation of androgen receptor expression; synthesis of androgens by tumor cells in local prostate cancer tissues; independent activation of androgen receptors by ligands other than androgens, such as growth factors or cytokines; changes in the expression of androgen co-regulatory factors; and changes in the expression of co-regulatory factors; breakdown of androgen receptors into androgen-independent active state isoforms; alterations in the interaction between mesenchymal components and epithelial cells within prostate cancer tissue; the presence of neuroendocrine cells, alterations in apoptotic mechanisms, mesenchymal transformation of prostate cancer cells, and the presence of tumor stem cells. At present, the main treatment for advanced desmoresistant prostate cancer is chemotherapy based on polyene paclitaxel chemotherapy, and in recent years, a new drug abiraterone has emerged, also to completely remove androgens of adrenal origin or synthesized by the tumor cells themselves in human body; in addition, there are targeted therapeutic drugs such as dendritic cells; thus improving the therapeutic effect, prolonging the patient’s survival and improving the quality of life.